Sukumar Nagendran, M.D.

Sukumar Nagendran, M.D.

President and Head of Research and Development and DirectoratTaysha Gene Therapies· In proxies 2022–2025

Pay in FY2022Taysha Gene Therapies stock -80.6% the same year

Sukumar Nagendran, M.D. was paid $1.4M in FY2022 (Dec). Taysha Gene Therapies stock fell 80.6% that year.

Pay$100 in the stock at the end of FY21 → $19
Pay is from the Summary Compensation Table of each Taysha Gene Therapies proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Taysha Gene TherapiesPublic company · 4 yr
    • President and Head of Research and Development and Director2022 – Present · 4 yrStock in role -67%
  2. Solid Biosciences Inc.Public company · 8 yr
    • Director2018 – Present · 8 yrNo stock prices for these years
  3. Health Sciences Acquisition Corp.Public company · Less than 1 yr
    • Director2019 – 2019 · Less than 1 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Taysha Gene TherapiesDirector · 5 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?